Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRAININ vs METHOHEXITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.
Tension headache,Migraine (off-label),Muscle contraction headache
Induction of anesthesia (FDA-approved),Maintenance of anesthesia (as an adjunct) (FDA-approved),Procedural sedation (off-label),Treatment of refractory status epilepticus (off-label)
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Terminal elimination half-life is 1.6–4.8 hours (mean ~3.9 hours) in adults. Context: Rapid redistribution shortens clinical duration; elimination half-life is longer in elderly and hepatic impairment.
Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes.
Primarily hepatic metabolism via CYP2B6 and other microsomal enzymes; undergoes oxidation and glucuronidation. Active metabolites are minimally important.
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Renal: <1% unchanged; hepatic metabolism followed by renal excretion of metabolites accounts for >95% of elimination. Fecal: negligible (<1%).
70-80% bound to albumin
85–90% bound to albumin.
0.3-0.5 L/kg; indicates moderate distribution into total body water
2.0–3.0 L/kg; context: High Vd due to extensive tissue distribution, especially to adipose tissue.
Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100%
Intramuscular: ~90–100%; Rectal: ~70–80%; Oral: not available (inactive due to first-pass metabolism).
Not studied; use caution with Cr Cl <30 m L/min. Avoid if severe renal impairment (Cr Cl <15 m L/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available.
No specific dose adjustment required for GFR 30-89 m L/min. For GFR <30 m L/min or dialysis: use with caution; consider reduced dose due to potential prolonged effect.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use alternative agent or reduce dose by 50% with careful titration.
Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred.
Induction: 1-2 mg/kg IV bolus. Maintenance: 0.5-1 mg/kg IV bolus as needed. Maximum single dose: 100 mg.
Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function.
Reduce initial dose by 25-50% (0.5-1 mg/kg IV) and titrate slowly due to increased sensitivity and prolonged recovery.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression and apnea; intravenous administration should be performed only by persons trained in the use of general anesthetics and able to maintain a patent airway and support ventilation. Continuous monitoring of respiratory function is required.
Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease.
Respiratory depression and apnea,Hypotension and bradycardia,Injection site reactions (thrombophlebitis, necrosis, extravasation),Risk of emergence delirium and postoperative confusion,Laryngospasm and bronchospasm,Accumulation with repeated doses in patients with hepatic or renal impairment
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
Hypersensitivity to methohexital or other barbiturates,Acute intermittent porphyria or porphyria variegata,Uncontrolled severe hypotension or shock,Status asthmaticus,Severe respiratory insufficiency,Known or suspected massive drug overdose
Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity.
No specific food interactions are documented for methohexital sodium. However, it is recommended to avoid heavy meals immediately before anesthesia to reduce risk of aspiration. Grapefruit juice may theoretically increase barbiturate levels by inhibiting CYP3A4, though clinical significance is unclear. Always follow pre-operative fasting instructions.
MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage.
Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal studies show developmental toxicity at high doses. In the second and third trimesters, there is a risk of fetal depression and neonatal withdrawal if used chronically near term. Avoid in first trimester if possible; use only if clearly needed.
Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital.
Methohexital enters breast milk in low amounts; the infant dose is estimated at <1% of maternal weight-adjusted dose. M/P ratio is approximately 0.5. Due to potential for neonatal sedation and the drug's short half-life, breastfeeding should be avoided for at least 4-6 hours after maternal administration.
No specific pharmacokinetic data for MICRAININ during pregnancy. Pregnancy can alter metabolism of acetaminophen and caffeine. Butalbital clearance may increase due to enhanced hepatic metabolism. However, dose adjustments are not typically recommended. Use the lowest effective dose for the shortest duration.
Pregnancy may alter pharmacokinetics: increased volume of distribution and clearance may require slightly higher initial doses for induction, but no specific dose adjustment is recommended; titrate to effect. Use lowest effective dose due to potential for fetal depression.
MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs.
METHOHEXITAL SODIUM is an ultra-short-acting barbiturate used for induction of general anesthesia. It has a rapid onset (less than 30 seconds) and short duration (5-10 minutes) due to redistribution. It is highly protein-bound and should be used with caution in patients with hypoalbuminemia. Contraindicated in porphyria. Avoid extravasation as it is a tissue irritant. May cause apnea, laryngospasm, and hypotension. Dose reduction needed in elderly or debilitated patients.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol while taking this medication.,Do not exceed 4000 mg acetaminophen per day from all sources.,This medication can be habit-forming; do not share with others.,May cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain.,Do not use for more than 5 days per week to avoid rebound headaches.
This medication will cause you to lose consciousness quickly and is only given by a healthcare professional.,You will be closely monitored during and after administration.,You may experience drowsiness, dizziness, or confusion after waking up; do not drive or operate machinery for 24 hours.,Inform your doctor if you have any allergies, porphyria, or liver/kidney disease.,Avoid alcohol and other sedatives for at least 24 hours after receiving this medication.
No interactions on record
"The combination of methohexital, a barbiturate anesthetic, and mesoridazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression and respiratory depression due to synergistic pharmacodynamic effects on GABAergic and dopaminergic pathways. This interaction may result in enhanced sedation, hypotension, and increased risk of respiratory arrest, particularly during induction or maintenance of anesthesia. Patients with underlying respiratory or cardiovascular compromise are at heightened risk for severe adverse outcomes."
"Methohexital, a barbiturate anesthetic, induces cytochrome P450 (CYP) 3A4 enzyme activity, accelerating the hepatic metabolism of azelnidipine, a dihydropyridine calcium channel blocker. This results in reduced plasma concentrations and diminished antihypertensive efficacy of azelnidipine, potentially leading to inadequate blood pressure control during concurrent use."
"Concomitant use of Methohexital, a barbiturate anesthetic with central nervous system (CNS) depressant effects, and Guanfacine, an alpha-2 adrenergic agonist with sedative properties, can lead to additive CNS depression. This may result in enhanced sedation, respiratory depression, hypotension, and bradycardia. Patients may experience excessive drowsiness, impaired cognitive and motor function, and increased risk of falls or respiratory compromise, particularly during anesthesia induction or recovery."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRAININ vs METHOHEXITAL SODIUM, answered by our medical review team.
MICRAININ is a Barbiturate Combination Analgesic that works by MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.. METHOHEXITAL SODIUM is a Barbiturate Anesthetic that works by Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRAININ and METHOHEXITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRAININ is: 2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.. The standard adult dose of METHOHEXITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRAININ and METHOHEXITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRAININ is classified as Category C. MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, par. METHOHEXITAL SODIUM is classified as Category C. Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.